Bath Savings Trust Co Sells 920 Shares of Balchem Co. (NASDAQ:BCPC)

Bath Savings Trust Co reduced its position in shares of Balchem Co. (NASDAQ:BCPC) by 2.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 36,087 shares of the basic materials company’s stock after selling 920 shares during the quarter. Bath Savings Trust Co owned 0.11% of Balchem worth $6,351,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Vanguard Group Inc. grew its position in Balchem by 3.8% during the first quarter. Vanguard Group Inc. now owns 3,935,935 shares of the basic materials company’s stock valued at $609,873,000 after buying an additional 144,423 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Balchem by 32.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 193,146 shares of the basic materials company’s stock worth $29,929,000 after acquiring an additional 47,036 shares during the last quarter. Conestoga Capital Advisors LLC grew its position in shares of Balchem by 2.7% during the 2nd quarter. Conestoga Capital Advisors LLC now owns 1,155,209 shares of the basic materials company’s stock valued at $177,844,000 after acquiring an additional 29,825 shares during the period. Congress Asset Management Co. MA increased its stake in shares of Balchem by 7.7% in the 1st quarter. Congress Asset Management Co. MA now owns 258,116 shares of the basic materials company’s stock worth $39,995,000 after purchasing an additional 18,459 shares in the last quarter. Finally, William Blair Investment Management LLC raised its holdings in Balchem by 8.4% in the 2nd quarter. William Blair Investment Management LLC now owns 233,831 shares of the basic materials company’s stock worth $35,998,000 after purchasing an additional 18,104 shares during the period. 87.91% of the stock is currently owned by institutional investors.

Insider Activity at Balchem

In other Balchem news, SVP Gunsteren Job Leonard Van sold 7,750 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $180.05, for a total value of $1,395,387.50. Following the completion of the transaction, the senior vice president now directly owns 8,540 shares in the company, valued at $1,537,627. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 1.25% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

BCPC has been the subject of several recent research reports. StockNews.com lowered Balchem from a “buy” rating to a “hold” rating in a report on Monday, July 29th. HC Wainwright boosted their price objective on Balchem from $170.00 to $185.00 and gave the company a “buy” rating in a research note on Wednesday, July 31st.

Balchem Stock Down 1.4 %

Shares of BCPC stock opened at $169.86 on Tuesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.83 and a quick ratio of 1.79. Balchem Co. has a one year low of $110.74 and a one year high of $186.03. The company’s fifty day moving average price is $171.05 and its 200-day moving average price is $160.67. The company has a market capitalization of $5.51 billion, a price-to-earnings ratio of 47.98, a PEG ratio of 5.54 and a beta of 0.65.

Balchem (NASDAQ:BCPC) last posted its quarterly earnings results on Friday, July 26th. The basic materials company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.95 by $0.03. The business had revenue of $234.08 million for the quarter, compared to analysts’ expectations of $241.26 million. Balchem had a return on equity of 10.94% and a net margin of 12.52%. Sell-side analysts expect that Balchem Co. will post 3.96 EPS for the current fiscal year.

Balchem Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.